Medtronic’s AccuRhythm AI algorithm technology has won the seventh annual MedTech Breakthrough Awards program as the "Best New Monitoring Solution."
Wow Design Studio Shutterstock
2002467086
Awards night
AccuRhythm AI is an artificial intelligence algorithm that improves the accuracy of heart rhythm event data from the Medtronic LINQ II insertable cardiac monitor (ICM) so physicians can better care for people with abnormal heart rhythms. The Medtronic AI technology was a standout from a field of nearly 4,000 nominations globally.
MedTech Breakthrough, an independent market intelligence organisation that recognises the top companies, technologies and products in the global health and medical technology market, conducts the MedTech Breakthrough Awards program. The LINQ family of insertable cardiac monitors (ICMs) provide continuous, long-term monitoring for patients with increased risk of abnormal heart rhythms who experience infrequent symptoms including dizziness, palpitations, syncope (fainting) and chest pain, thereby requiring long-term monitoring or ongoing management.
Stacey Churchwell, vice president and general manager of the Cardiovascular Diagnostics and Services business within the Cardiac Rhythm Management Operating Unit, said: "We are thrilled to win the MedTech Breakthrough Award for a technology that makes such a profound impact on patients and helps clinicians focus on cardiac events that are most relevant. We look forward to building on this AI technology with future enhancements across our LINQ family of ICMs."
Medtronic introduced AccuRhythm AI algorithms in 2022 to patients and clinicians in Australia, countries throughout Europe, the United States, and New Zealand to help improve the accuracy of information physicians receive so they can better treat their patients. The two AI algorithms — specific to the most common ICM false alerts, atrial fibrillation (AF) and pause (asystole) — have been shown to reduce the number of false alerts by as much as 84%, saving clinicians approximately 319 hours of clinic review time annually (for every 200 LINQ II patients).
An enhancement to the AF algorithm for the LINQ II ICM further reduces AF false alerts, which is anticipated to further reduce clinic review time.
